What Is Ceruletide? Definition and What Research Reports

Ceruletide is a decapeptide — a chain of ten amino acids — that was originally isolated from the skin secretions of an Australian tree frog and that closely resembles the biologically active C-terminal region of the mammalian gut hormone cholecystokinin (CCK). Because of that structural similarity, it is classified pharmacologically as a CCK receptor agonist, the description used in a 2020 review of the compound published in the Journal of Pain Research (PMID 32021401). The molecule carries a sulfated tyrosine residue, a feature it shares with CCK and gastrin and one that is generally considered important for its receptor binding. In practice, the word "ceruletide" is used in two overlapping ways in the peptide literature: as the name of a pharmacological agent given to animals or patients in published studies, and as the name of a laboratory reagent used to model disease in rodents. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment.

Origin and Molecular Class

Ceruletide belongs to the family of amphibian skin peptides — a large group of bioactive molecules found in frog and toad secretions that frequently mirror vertebrate hormones. Its mammalian counterparts are the CCK–gastrin family of gut peptides, which regulate gallbladder contraction, pancreatic enzyme secretion and gastrointestinal motility, and which also act at receptors in the central nervous system. Ceruletide is therefore usually described as a peptide hormone analogue rather than as a synthetic designer peptide: it is a naturally occurring sequence that happens to be a potent agonist at mammalian CCK receptors.

In classification terms, the relevant labels are:

• Chemical class: linear decapeptide, sulfated.
• Pharmacological class: cholecystokinin (CCK) receptor agonist, as described in a 2020 review (PMID 32021401).
• Biological origin: amphibian skin secretion; produced synthetically for research and pharmaceutical use.

Naming: Ceruletide, Caerulein and Cerulein

One of the most common sources of confusion around this term is spelling. The same molecule appears in the indexed literature under several names, and a reader searching one form will miss papers filed under another.

All three refer to the same decapeptide. The variation matters mainly for literature searching: the pancreatitis-model literature is indexed overwhelmingly under "cerulein", while pain, stroke and diagnostic papers more often use "ceruletide".

How the Term Is Used in Peptide Research

1. As a disease-modelling reagent

The single most frequent appearance of this peptide in the biomedical literature is not as a candidate therapy but as a tool. Administering the peptide to rodents produces a reproducible pancreatic injury that researchers use as a standard model of acute pancreatitis, and other test compounds are then evaluated against it. A 2019 rat study published in Annals of Surgical Treatment and Research used exactly this approach, examining whether the steroidal sapogenin ruscogenin had protective and therapeutic effects on cerulein-induced experimental acute pancreatitis (PMID 31824881). In papers of this kind, the peptide is the insult, not the intervention — an important distinction when reading abstracts quickly.

2. As a gastrointestinal and diagnostic stimulant

Because CCK agonism triggers gallbladder emptying, the peptide has been used as a provocative stimulus in diagnostic testing. A 2008 veterinary study in the Journal of Veterinary Internal Medicine compared postprandial and ceruletide-stimulated serum bile acid testing in dogs, evaluating ceruletide stimulation as an alternative to a meal for provoking gallbladder contraction during bile acid assessment (PMID 18537882). This diagnostic use — provoking a physiological response so that a downstream measurement can be interpreted — is a recurring theme in the older literature on this molecule.

3. As a CCK-pathway probe in pain and CNS research

CCK receptors are present in the central nervous system as well as the gut, which is why the peptide also appears in neuroscience and analgesia papers. A 2020 article framed the compound as a rediscovered analgesic candidate and reviewed its status as a CCK agonist in the context of pain research (PMID 32021401). Separately, a 2022 paper in Neurotherapeutics investigated ceruletide combined with alpha-1 antitrypsin as a novel combination therapy in ischemic stroke research (PMID 35226340).

What the Published Literature Reports

Across the verified papers summarised here, the reported work falls into distinct and largely non-overlapping areas. In the pancreatitis literature, researchers used cerulein specifically to generate experimental acute pancreatitis in rats and then tested whether a separate compound, ruscogenin, exerted protective or therapeutic effects against that induced injury (PMID 31824881). In the veterinary diagnostic literature, the study compared ceruletide-stimulated serum bile acid concentrations with postprandial values in dogs (PMID 18537882). In pain research, a 2020 review revisited the compound as an analgesic drug candidate on the basis of its CCK agonist activity (PMID 32021401), and in cerebrovascular research a 2022 study examined it as one half of a combination with alpha-1 antitrypsin in ischemic stroke (PMID 35226340).

None of these reports is interchangeable with the others. A finding produced in a rodent pancreatitis model, in a canine diagnostic protocol, or in a preclinical stroke study does not transfer to human clinical practice, and the verified literature summarised on this page does not establish outcomes in humans.

Effects Observed in Animal Models: What Studies Report

The most notable safety-relevant point about this molecule is structural to how it is used: the compound is itself the agent used to produce pancreatic injury in laboratory animals, as reflected in the design of the 2019 rat study of cerulein-induced experimental acute pancreatitis (PMID 31824881). In other words, a well-documented biological effect of this peptide in rodents, at the exposures used in that model, is pancreatic inflammation — which is precisely why it functions as a model reagent.

Beyond that, the verified papers cited here did not report a systematic adverse-event profile in their titles or abstracts, and this page does not extrapolate one. Specific doses, dosing schedules, routes of administration and tolerability data are not reproduced here, because the verified source set does not support stating them. Readers reviewing this literature would need to consult the full texts of the individual studies and the wider CCK pharmacology literature for those details.

Summary of the Entry

• What it is: a sulfated decapeptide of amphibian origin that acts as a cholecystokinin receptor agonist (PMID 32021401).
• Also written as: caerulein, cerulein.
• Main research role: reagent for inducing experimental acute pancreatitis in rodents (PMID 31824881).
• Other reported contexts: gallbladder/bile acid stimulation testing in dogs (PMID 18537882), analgesia discussion (PMID 32021401) and ischemic stroke combination research (PMID 35226340).
• What this page is not: a protocol, a recommendation, or a statement about availability. It is a definitional reference entry.

References

• Examination of protective and therapeutic effects of ruscogenin on cerulein-induced experimental acute pancreatitis in rats (Annals of Surgical Treatment and Research, 2019)
• Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke (Neurotherapeutics, 2022)
• Rediscovery of Ceruletide, a CCK Agonist, as an Analgesic Drug (Journal of Pain Research, 2020)
• Comparison of postprandial and ceruletide serum bile acid stimulation in dogs (Journal of Veterinary Internal Medicine, 2008)